Drug-induced psychosis: How to avoid star gazing in schizophrenia research by looking at more obvious sources of light

Frontiers in Behavioral Neuroscience

Volumn , Issue JANUARY, 2011, Pages

  Paparelli, Alessandra ^a   Di Forti, Marta ^a   Morrison, Paul D ^a   Murray, Robin M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Amphetamines; Cannabis; LSD; PCP; Psychosis; Schizophrenia

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; AMISULPRIDE; AMPHETAMINE DERIVATIVE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABIS; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE; DRONABINOL; GLUTAMIC ACID; KETAMINE; LYSERGIDE; METHAMPHETAMINE; N,N DIMETHYLTRYPTAMINE; OLANZAPINE; PHENCYCLIDINE; PLACEBO; POMAGLUMETAD METHIONIL; PSILOCYBINE; RIMONABANT; SEROTONIN; SEROTONIN 2A RECEPTOR;

AGITATION; ATTENTION DISTURBANCE; CANNABIS SMOKING; COCAINE DEPENDENCE; DOPAMINE RELEASE; DRUG INDUCED PSYCHOSIS; DRUG MECHANISM; GENETIC PREDISPOSITION; HALLUCINATION; HUMAN; LOW DRUG DOSE; MEMORY DISORDER; MOTOR DYSFUNCTION; NONHUMAN; ONSET AGE; PROPRIOCEPTION; PROTEIN FUNCTION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT;

EID: 84855203087     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2011.00001     Document Type: Review

References (140)

1. Adermark, L., Talani, G., and Lovinger, D. M. (2009). Endocannabinoiddependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur. J. Neurosci. 29, 32-41.
2. Anden, N. E., Corrodi, H., Fuxe, K., and Hokfelt, T. (1968). Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide. Br. J. Pharmacol. 34, 1-7.
3. Andreasson, S., Allebeck, P., Engstrom, A., and Rydberg, U. (1987). Cannabis and Schizophrenia: a longitudinal study of Swedish conscripts. Lancet 26, 1483-1486.
4. Angrist, B., Sathananthan, G., Wilk, S., and Gershon, S. (1974). Amphetamine psychosis: behavioural and biochemical aspects. J. Psychiatr. Res. 11, 13-23
5. Anis, N. A., Berry, S. C., Burton, N. R., and Lodge, D. (1983). The dissociative anesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-d-aspartate. Br. J. Pharmacol. 79, 565-575.
6. Arora, R. C., and Meltzer, H. Y. (1991). Serotonin 2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J. Neural Transm. 85, 19-29.
7. Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., and Moffitt, T. E. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325, 1212-1213.
8. Barkus, E., Morrison, P. D., Vuletic, D., Dickson, J. C., Ell, P. J., Pilowsky, L. S., Brenneisen, R., Holt, D. W., Powell, J., Kapur, S., and Murray, R. M. (2010). Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study. J. Psychopharmacol. doi: 10.1177/0269881110382465. [Epub ahead of print].
9. Barnett, J. H., Werners, U., Secher, S. M., Hill, K. E, Brazil, R., Masson, K., Pernet, D. E., Kirkbride, J. B., Murray, G. K., Bullmore, E. T., and Jones, P. B. (2007). Substance use in a population-based clinic sample of people with firstepisode psychosis. Br. J. Psychiatry 190, 515-520.
10. Beringer, K. (1927). Der Meskalinrausch. Seine Geschichte und Erscheinungsweise. Berlin: Julius Springer
11. Bhattacharyya, S., Morrison, P. D., FusarPoli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., Mehta, M. A., Stone, J. M., Tunstall, N., Giampietro, V., Kapur, S., Murray, R. M., Zuardi, A. W., Crippa, J. A., Atakan, Z., and McGuire, P. K. (2009). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35, 764-774.
12. Boileau, I., Dagher, A., Leyton, M., Gunn, R. N., Baker, G. B., Diksic, M., and Benkelfat, C. (2006). Modeling sensitization to stimulants in humans. An [11C] Raclopride/Positron Emission Tomography Study in healthy me. Arch. Gen. Psychiatry 63, 1386-1395
13. Bosi, D., Hallak, J., Dursun, S., Deakin, J., and Zuardi, A. (2003). Effects of cannabidiol on (s)-ketamine-induced psychopathology in healthy volunteers. J. Psychopharmacol. 17, A55
14. Bossong, M. G., van Berckel, B. N., Boellaard, R., Zuurman, L., Schuit, R. C., Windhorst, A. D., van Gerven, J. M., Ramsey, N. F., Lammertsma, A. A., and Kahn, R. S. (2009). Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34, 759-766.
15. Bousman, C. A., Glatt, S. J., Everall, I. P., and Tsuang, M. T. (2009). Genetic association studies of methamphetamine use disorders: a systematic review and synthesis. Am. J. Med. Genet. 150B, 1025-1049.
16. Breakey, W. R., Goodell, H., Lorenz, P. C., and McHugh, P. R. (1974). Hallucinogenic drugs as precipitants of schizophrenia. Psychol. Med. 4, 255-261.
17. Breier, A., Su, T. P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., and Pickar, D. (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U.S.A. 94, 2569-2574.
18. Broome, M. R., Woolley, J. B., Tabraham, P., Johns, L. C., Bramon, E., Murray, G. K., Pariante, C., McGuire, P. K., and Murray, R. M. (2005). What causes the onset of psychosis? Schizophr. Res. 79, 23-34.
19. Calabresi, P., Picconi, B., Tozzi, A., and Di Filippo, M. (2007). Dopaminemediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 30, 211-219.
20. Carlsson, A., and Lindqvist, M. (1963). Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 20, 140-144.
21. Carter, O. L., Hasler, F., Pettigrew, J. D., Wallis, G. M., Liu, G. B., and Vollenweider, F. X. (2007). Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology 195, 415-424.
22. Centonze, D., Battista, N., Rossi, S., Mercuri, N. B., Finazzi-Agro, A., Bernardi, G., Calabresi, P., and Maccarrone, M. (2004). A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal GABAergic transmission. Neuropsychopharmacology 29, 1488-1497.
23. Centonze, D., Rossi, S., De Chiara, V., Prosperetti, C., Battista, N., Bernardi, G., Mercuri, N. B., Usiello, A., and Maccarrone, M. (2007). Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors. Eur. J. Neurosci. 25, 1631-1640.
24. Chen, C. K., Lin, S. K., Sham, P. C., Ball, D., Loh, E. W., Hsiao, C. C., Chiang, Y. L., Ree, S. C., Lee, C. H., and Murray, R. M. (2003). Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol. Med. 33, 1407-1414.
25. Chevaleyre, V., Takahashi, K. A., and Castillo, P. E. (2006). Endocannabinoidmediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 29, 37-76
26. Chiang, Y. C., and Chen, J. C. (2007). The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. J. Neurochem. 103, 2505-2517.
27. Collins, V. J, Gorospe, C. A., and Rovenstine, E. A. (1960). Intravenous nonbarbiturate, non narcotic analgesics: preliminary studies. I. Cyclohexylamines. Anesth. Analg. 39, 303-306.
28. Connell, P. H. (1958). Amphetamine Psychosis. Maudsley Monographs. No. 5. London: Oxford University Press
29. Corbille, A. G., Valjent, E., Marsicano, G., Ledent, C., Lutz, B., Herve, D., and Girault, J. (2007). Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J. Neurosci. 27, 6937-6947.
30. Deakin, J. F., and Simpson, D. C. (1997). A two-process theory of schizophrenia: evidence from studies in post-mortem brain. J. Psych. Res. 31, 277-295.
31. Di Forti, M., Lappin, J. M., and Murray, R. M. (2007a). Risk factors for schizophrenia. All roads lead to dopamine. Eur. Neuropsychopharmacol. 17, S101-S107.
32. Di Forti, M., Morrison, P. D., Butt, A., and Murray, R. M. (2007b). Cannabis use and psychiatric and cognitive disorders: the chicken or the egg? Curr. Opin. Psychiatry 20, 228-234.
33. Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Reis Marques, T., Handley, R., Aas, M., Luzi, S., Russo, M., Paparelli, A., Butt, A., Stilo, S. A., Wiffen, B., Powell, J., and Murray, R. M. (2009). Use of high potency cannabis is associated with a greater risk of psychosis. Br. J. Psychiatry 195, 488-491.
34. D'Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., and Krystal, J. H. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 57, 594-608.
35. D'Souza, D. C., Braley, G., Blaise, R., Vendetti, M., Oliver, S., Pittman, B., Ranganathan, M., Bhakta, S., Zimolo, Z., Cooper, T., and Perry, E. (2008). Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta9-tetrahydrocannabinol in humans. Psychopharmacology 198, 587-603
36. D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Yu-Te, W., Braley, G., Gueorguieva, R., and Harrison, K. J. (2004). The psychotomimetic effects of intravenous delta9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29, 1558-1572.
37. Espelin, D. E., and Done, A. K. (1968). Amphetamine poisoning: effectiveness of chiorpromazine. N. Engl. J. Med. 278, 1361-1365.
38. European Monitoring Centre for Drugs, and Drug Addiction Annual Report. (2009). The State of the Drugs Problem in Europe. Luxembourg: Publications Office of the European Union 2009, 99
39. Fergusson, D. M., Horwood, L. J., and Swain-Campbell, N. R. (2003). Cannabis dependence and psychotic symptoms in young people. Psychol. Med. 33, 15-21.
40. Fergusson, D. M., Poulton, R., Smith, P. F., and Boden, J. M. (2006). Cannabis and psychosis. BMJ 332, 172-175.
41. Franzen, F., and Gross, H. (1965). Tryptamine, N,Ndimethyltryptamine, N,Ndimethyl-5-hydroxytryptamine and 5-methoxytryptamine in human blood and urine. Nature 206, 1052
42. Freiman, I., Anton, A., Monyer, H., Urbanski, M. J., and Szabo, B. (2006). Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. J. Physiol. 575, 789-806.
43. Freund, T. F., Katona, I., and Piomelli, D. (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83, 1017-1066.
44. Gerdeman, G. L., Ronesi, J., and Lovinger, D. M. (2002). Postsynaptic endocannabinoid release is critical to longterm depression in the striatum. Nat. Neurosci. 5, 446-451.
45. Gillin, J. C., Kaplan, J., Stillman, R., and Wyall, R. J. (1976). The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine. Am. J. Psychiatry 133, 203-208.
46. Giuffrida, A., Parsons, L. H., Kerr, T. M., Rodriguez de Fonseca, F., Navarro, M., and Piomelli, D. (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2, 358-363.
47. Glennon, R. A., Rosecrans, J. A., and Young, R. (1983). Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents. Med. Res. Rev. 3, 289-340.
48. Glenthøj, B.Y., and Hemmingsen, R. (1997). Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 21, 22-46.
49. Gonzalez-Maeso, J., and Sealfon, S. (2009). Psychedelics and schizophrenia. Trends Neurosci. 32, 225-232.
50. Graybiel, A. M. (2005). The basal ganglia: learning new tricks and loving it. Curr. Opin. Neurobiol. 15, 638-644.
51. Green, B., Young, R., and Kavanagh, D. (2005). Cannabis use and misuse prevalence among people with psychosis. Br. J. Psychiatry 187, 306-313.
52. Greifenstein, F. E., Yoskitake, J., DeVault, M., and Gajewski, J. E. (1958). A study of 1-aryl-cyclohexylamine for anesthesia. Anesth. Analg. 37, 283-294.
53. Grelotti, D. G., Kanayama, G., and Pope, H. G. (2010). Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy. Am. J. Psychiatry 167, 17-23.
54. Gurevich, E. V., and Joyce, J. N. (1997). Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry 42, 529-545.
55. Henquet, C., Murray, R. M., Linszen, D., and van Os, J. (2005). The environment and schizophrenia: the role of cannabis use. Schizophr. Bull. 31, 608-612.
56. Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R., and Rice, K. C. (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563-583.
57. Hofmann, A. (1980). LSD My Problem Child. New York: McGraw-Hill
58. Houk, J. C., Bastianen, C., Fansler, D., Fishbach, A., Fraser, D., Reber, P. J., Roy, S. A., and Simo, L. S. (2007). Action selection and refinement in subcortical loops through basal ganglia and cerebellum. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 362, 1573-1583
59. Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Nelson, R. A., Moolchan, E. T., and Frank, R. A. (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry 58, 322-328.
60. Iyo, M., Sekine, Y., and Mori, N. (2004). Neuromechanism of developing methamphetamine psychosis: a neuroimaging study. Ann. N. Y. Acad. Sci. 1025, 288-329.
61. Javitt, D. C., and Zukin, S. R. (1990). Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308.
62. Johnstone, M., Evans, V., and Baigel, S. (1958). Sernyl (Cl-395) in clinical anesthesia. Br. J. Anaesth. 31, 433-439.
63. Joyce, J. N., Shane, A., Lexow, N., Winokur, A., Casanova, M., and Kleinmann, J. E. (1993). Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8, 315-336
64. Kapur, D., and Mamo, D. (2003). Half a century of antipsychotics and still a central role for opamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 1981-1990.
65. Kim, J. S., Kornhuber, H. H., SchmidBurgk, W., and Holzmuller, B. (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20, 379-382.
66. Kotz, A., and Merkel, P. (1926). Zur Kenntnis hydroaromatischer Alkamine. J. Prakt. Chem. 113, 49
67. Kreitzer, A. C., and Malenka, R. C. (2005). Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J. Neurosci. 25, 10537-10545.
68. Kreitzer, A. C., and Malenka, R. C. (2007). Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445, 643-647.
69. Kreitzer, A. C., and Malenka, R. C. (2008). Striatal plasticity and basal ganglia circuit function. Neuron 60, 543-554
70. Laruelle, M., Abi-Dargham, A., van Dyck, C. H, Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., Baldwin, R. M., Seibyl, J. P., Krystal, J. H., Charney, D. S., and Innis, R. B. (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U.S.A. 93, 9235-9240.
71. Lesscher, H. M., Hoogveld, E., Burbach, J. P., van Ree, J. M., and Gerrits, M. A. (2005). Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. Eur. Neuropsychopharmacol. 15, 31-37
72. Leweke, F. M. (2007). Antipsychotic effects of cannabidiol. Eur. Psychiatry 24, s207.
73. Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., and Piomelli, D. (1999a). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10, 1665-1669.
74. Leweke, F. M., Schneider, U., Thies, M., Münte, T. F., and Emrich, H. M. (1999b). Effects of synthetic D9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology 142, 230-235
75. Leweke, F. M., Schneider, U., Radwan, M., Schmidt, E., and Emrich, H. M. (2000). Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol. Biochem. Behav. 66, 175-181.
76. Lieberman, J. A., Kane, J. M., and Alvir, J. (1987). Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91, 415-433.
77. Lieberman, J. A, Mailman, R. B., Duncan, G., Sikich, L., Chakos, M., Nichols D. E., and Kraus, J. E. (1998). Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiatry 44, 1099-1117.
78. Ljeberman, J. A., Klnon, B. J., and Loebel, A. D. (1990). Dopaminergic mechanisms in idiopathic and druginduced psychoses. Schizoph. Bull. 16, 97-110.
79. Long, L. E., Malone, D. T., and Taylor, D. A. (2006). Cannabidiol reverses MK-801induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31, 795-803.
80. Luby, E. D., Cohen, B. D., Rosenbaum, F., Gottlieb, J., and Kelley, R. (1959). Study of a new schizophrenomimetic drug, sernyl. Arch. Neurol. Psychiatry 81, 363-369.
81. Luby, E. D., Gottlieb, J. S., Cohen, B. D., Rosenbaum, G., and Domino, E. F. (1962). Model psychoses and schizophrenia. Am. J. Psychiatry 119, 61-67.
82. Lupica, C. R., and Riegel, A. C. (2005). Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 48, 1105-1116.
83. MacDonald, A. W., and Schulz, S. C. (2009). What we know: findings that every theory of schizophrenia should explain. Schizophr. Bull. 35, 493-508
84. Manske, R. (1931). A synthesis of the methyltryptamines and some derivatives. Can. J. Res. 5, 592-600.
85. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
86. Matyas, F., Urban, G. M., Watanabe, M., Mackie, K., Zimmer, A., Freund, T. F., and Katona, I. (2008). Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 54, 95-107.
87. McGrath, J., Welham, J., Scott, J., Varghese, D., Degenhardt, L., Hayatbakhsh, M. R., Alati, R., Williams, G. M., Bor, W., and Najman, J. M. (2010). Association between cannabis use and psychosisrelated outcomes using sibling pair analysis in a cohort of young adult. Arch. Gen. Psychiatry 67, 440-447
88. McGraw-Hill. (1993). Encyclopedia of Science and Technology, 5th Edn. New York: The McGraw-Hill Companies Inc.
89. Melis, M., Perra, S., Muntoni, A. L., Pillolla, G., Lutz, B., Marsicano, G., Di Marzo, V., Gessa, G. L., and Pistis, M. (2004). Prefrontal cortex stimulation induces 2-arachidonoyl-glycerolmediated suppression of excitation in dopamine neurons. J. Neurosci. 24, 10707-10715.
90. Meltzer, H. Y. (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21, 106s-115s.
91. Meltzer, H. Y., Arvanitis, L., Bauer, D., and Rein, W. (2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 161, 975-984.
92. Mita, T., Hanada, S., Nishino, N., Kuno, T., Nakai, H., Yamdori, T., Mizoi, Y., and Tanaka, C. (1986). Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol. Psychiatry 21, 1407-1414.
93. Moore, T. H. M., Zammit, S., LingfordHughes, A., Barnes, T. R. E., Jones, P. B., Burke, M., and Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319-328.
94. Moreira, F. A., and Guimaraes, F. S. (2005). Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur. J. Pharmacol. 512, 199-205.
95. Morrison, P. D., Zois, V., McKeown, D. A., Lee, T. D., Holt, D. W., Powell, J. F., Kapur, S., and Murray, R. M. (2009). The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol. Med. 39, 1607-1616
96. Murray, R. M., Lappin, J., and Di Forti, M. (2008). Schizophrenia: from developmental deviance to dopamine dysregulation. Eur. Neuropsychopharmacol. 18, S129-S134.
97. Murray, R. M., Oon, M. C. H., Rodnight, R., Birley, J. L. T., and Smith, A. (1979). Increased excretion of dimethyltryptamine and certain features of psychosis. A possible association. Arch. Gen. Psychiatry 36, 644-664.
98. Narasimhachari, N., Avalos, J., Fujimori, M., and Himwich, H. E. (1972). Studies of drugfree schizophrenics and controls. Biol. Psychiatry 5, 311-318.
99. Nichols, D. E. (2004). Hallucinogens. Pharmacol. Ther. 101, 131-181
100. Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., Mosolov, S. N., Neznanov, N. G., Reznik, A. M., Smulevich, A. B., Tochilov, V. A., Johnson, B. G., Monn, J. A., and Schoepp, D. D. (2007). Activation of mGluR2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat. Med. 13, 1102-1107.
101. Peleg-Raibstein, D., Yee, B. J., and Hauser, J. (2009). The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms? Psychopharmacology 206, 603-621
102. Pertwee, R. G. (2007). The diverse CB(1) and CB(2) receptor pharmacology of three plant cannabinoids: delta(9) t{stroke}etrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199-215.
103. Pomarol-Clotet, E., Honey, G. D., Murray, G. K., Corlett, P. R., Abasalom, A. R., Lee, M., McKenna, P. J., Bullmore, E. T., and Fletcher, P. C. (2006). Psychological effects of ketamine in healthy volunteers. Br. J. Psychiatry 189, 173-179.
104. Potter, D. J., Clark, P., and Brown, M. B. (2008). Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J. Forensic Sci. 53, 90-94.
105. Rasmussen, H., Erritzoe, D., Andersen, R., Ebdrup, B. H., Aggernaes, B., Oranje, B., Kalbitzer, J., Madsen, J., Pinborg, L. H., Baare', W., Svarer, C., Lublin, H., Knudsen, G. M., and Glenthoj, B. (2010). Decreased frontal serotonin2A receptor binding in antipsychoticnaive patients with first-episode schizophrenia. Arch. Gen. Psychiatry 67, 9-16.
106. Robbe, D., Kopf, M., Remaury, A., Bockaert, J., and Manzoni, O. J. (2002). Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A. 99, 8384-8388.
107. Rodriguez, M. A. (2007). A methodology for studying various interpretations of the N,N-dimethyltryptamine-induced alternate reality. Nat. Neurosci. 21, 67-84.
108. Rosenbaum, G., Cohen, B. D., Luby, E. D., Gottlieb, J. S., and Yelen, D. (1959). Cornparisons of Sernyl with other drugs. Arch. Gen. Psychiatry 1, 651-656.
109. Seeman, P., and Tallerico, T. (2005). Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol. Psychiatry 10, 877-883.
110. Shaw, E., and Woolley, D. W. (1956). Some serotonin-like activities of lysergic acid diethylamide. Science 124, 121
111. Smith, M. J., Thirthalli, J., Abdallah, A. B., Murray, R. M., and Cottler, L. B. (2009). Prevalence of psychotic symptoms in substance users: a comparison across substances. Compr. Psychiatry 50, 245-250.
112. Snyder, E. M., and Murphy, M. R. (2008). Schizophrenia therapy: beyond atypical antipsychotics. Nat. Rev. 7, 471-472.
113. Snyder, S. H. (1972). Catecholamines in the brain as mediators of amphetamine psychosis. Arch. Gen. Psychiatry 27, 169-179.
114. Stokes, P. R., Mehta, M. A., Curran, H. V., Breen, G., and Grasby, P. M. (2009). Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage 48, 186-190.
115. Stokes, P. R. A., Egerton, A., Watson, B., Reid, A., Breen, G., Lingford-Hughes, A., Nutt, D. J., and Mehta, M. A. (2010). Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. Neuroimage 52, 1521-1527.
116. Strassman, R. J. (1984). Adverse reaction to psychedelic drugs. A review of the literature. J. Nerv. Ment. Dis. 172, 577-595.
117. Strassman, R. J. (1991). Human hallucinogenic drug research in the United States: a present-day case history and review of the process. J. Psychoactive Drug 23, 29-38.
118. Szara, S. (1956). Dimethyltryptamine: its metabolism in man: the relation of its psychotic effect to serotonin metabolism. Experientia 12, 441-442.
119. Tamminga, C. A., and Holcomb, H. H. (2005). Phenotype of schizophrenia: a review and formulation. Mol. Psychiatry 10, 27-39.
120. Tandon, R., Keshavan, M. S., and Nasrallah, H. A. (2008). Schizophrenia, "Just the Facts" What we know in 2008. Epidemiology and etiology. Schizophr. Res. 102, 1-18.
121. Tatetsu, S., Goto, A., and Fujiwara, T. (1956). Psychostimulant Toxicosis. Tokyo: Igakushoin.
122. Thiemann, G., Di Marzo, V., Molleman, A., and Hasenohrl, R. U. (2008a). The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamineinduced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. Pharmacol. Biochem. Behav. 89, 384-391.
123. Thiemann, G., van der Stelt, M., Petrosino, S., Molleman, A., Di Marzo, V., and Hasenohrl, R. U. (2008b). The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. Behav. Brain Res. 187, 289-296.
124. Tsuang, M. T., Bar, J. L., Stone, W. S., and Faraone, S. V. (2004). Geneenvironment interactions in mental disorders. World Psychiatry 3, 73-83.
125. Uchigashima, M., Narushima, M., Fukaya, M., Katona, I., Kano, M., andWatanabe, M. (2007). Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J. Neurosci. 27, 3663-3676.
126. United Nations Office on Drugs, and Crime (UNODC). (2009). "Patterns and trends of amphetamine-type stimulants and other drugs in East and South-East Asia (and neighbouring regions)," in Annual Report. Vienna: Vienna International Centre
127. Van Os, J., Bak, M., Hanssen, M., Bij, R. V., de Graaf, R., and Verdoux, H. (2002). Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 156, 319-327.
128. Van Rossum, J. M. (1967). "The significance of dopamine-receptor blockade for the action of neuroleptic drugs," in Neuropsychopharmacology, Proceedings 5th Collegium Internationale Neuropsychopharmacologicum, eds H. Brill, J. Cole, P. Deniker, H. Hippius, and P. B. Bradley (Amsterdam: Excerpta Medica Foundation), 321-329.
129. Vardy, M. M., and Kay, S. R. (1983). LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry. Arch. Gen. Psychiatry 40, 877-883.
130. Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Maguire, P., Stadelmann, O., and Angst, J. (1997). Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16, 357-372.
131. Vollenweider, F. X., VollenweiderScherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., and Hell, D. (1998). Psilocybin induces schizophrenialike psychosis in humans via a serotonin-2 agonist action. Neuroreport 9, 3897-3902.
132. Yin, H. H., and Knowlton, B. J. (2006). The role of the basal ganglia in habit formation. Nat. Rev. 7, 464-476
133. Yin, H. H., and Lovinger, D. M. (2006). Frequency-specific and D2 receptormediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc. Natl. Acad. Sci. U.S.A. 103, 8251-8256.
134. Zammit, L. S., Allebeck, P., Andreasson, S., Lundberg, I., and Lewis, G. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325, 1199-1212.
135. Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S. M., and Tumas, V. (2009). Cannabidiol for the treatment of psychosis in Parkinson's disease. J. Psychopharmacol. 23, 979-983.
136. Zuardi, A. W. (2006). History of cannabis as a medicine: a review. Rev. Bras. Psiquiatr. 28, 153-157.
137. Zuardi, A. W., Rodrigues, J. A., and Cunha, J. M. (1991). Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 104, 260-264.
138. Zuardi, A. W, Shirakawa, I., Finkelfarb, E., and Karniol, I. G. (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76, 245-250.
139. Zuurman, L., Passier, P. C., de Kam, M. L., Kleijn, H. J., Cohen, A. F., and van Gerven, J.M. (2009). Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers. J. Psychopharmacol. 24, 1689-1696.
140. Zuurman, L., Roy, C., Schoemaker, R., Amatsaleh, A., Guimaeres, L., Pinquier, J., Cohen, A. F., and van Germen, J. M. A. (2010). Inhibition of THCinduced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. J. Psychopharmacol. 24, 363-371.